Compare COHU & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | ELVN |
|---|---|---|
| Founded | 1947 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | 2020 |
| Metric | COHU | ELVN |
|---|---|---|
| Price | $23.88 | $16.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $29.33 | ★ $41.20 |
| AVG Volume (30 Days) | 503.5K | ★ 816.7K |
| Earning Date | 02-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $424,848,000.00 | N/A |
| Revenue This Year | $14.95 | N/A |
| Revenue Next Year | $12.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.57 | $13.30 |
| 52 Week High | $28.03 | $25.37 |
| Indicator | COHU | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 37.87 |
| Support Level | $22.80 | $15.71 |
| Resistance Level | $23.99 | $18.05 |
| Average True Range (ATR) | 0.69 | 1.46 |
| MACD | -0.16 | -0.26 |
| Stochastic Oscillator | 37.46 | 12.74 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection).
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.